- Home
- GERN vs UMAC Comparison
GERN vs UMAC Comparison
Compare GERN & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GERN | UMAC |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | 258 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.0M | 795.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | GERN | UMAC |
|---|---|---|
| Price | $1.29 | $21.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.17 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 8.1M | 3.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.73 |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $11,199,217.00 |
| Revenue This Year | $26.91 | $115.39 |
| Revenue Next Year | $43.75 | $101.44 |
| P/E Ratio | ★ N/A | $97.38 |
| Revenue Growth | N/A | ★ 101.23 |
| 52 Week Low | $1.04 | $7.25 |
| 52 Week High | $2.01 | $34.36 |
Technical Indicators
Market Signals| Indicator | GERN | UMAC |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 51.56 |
| Support Level | $1.24 | $12.23 |
| Resistance Level | $1.46 | $20.95 |
| Average True Range (ATR) | 0.07 | 2.02 |
| MACD | -0.02 | 0.23 |
| Stochastic Oscillator | 6.52 | 79.40 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
About UMAC Unusual Machines Inc.
Unusual Machines Inc is engaged in manufactures and sells drone components and drones across a diversified brand portfolio through business-to-business (B2B) sales and a curated retail channel.